Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of CC-4047 with or without prednisone in myelofibrosis with myeloid metaplasia
2006-004553-17Phase 2Terminated
- Sponsor
- Celgene Corporation
- Start
- Jan 2007
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pomalidomide in primary myelofibrosis (PMF) (2 arms), sponsored by Celgene Corporation. Primary endpoint: Best overall response over first 6 cycles. Started Jan 2007; status: terminated.
02
Drugs
pomalidomide
03
Conditions
primary myelofibrosis (PMF)
Beyond the preview
Go deeper on 2006-004553-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004553-17.